StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)
August 11, 2026 5:10 AM
Mizuho analyst Uy Ear reiterated an Outperform rating and $19.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD)The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
